CNTB Collar Strategy
CNTB (Connect Biopharma Holdings Limited), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.
CNTB (Connect Biopharma Holdings Limited) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $138.5M, a beta of -0.20 versus the broader market, a 52-week range of 0.7-3.82, average daily share volume of 258K, a public-listing history dating back to 2021, approximately 62 full-time employees. These structural characteristics shape how CNTB stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of -0.20 indicates CNTB has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a collar on CNTB?
A collar pairs long stock with a protective out-of-the-money put financed by a short out-of-the-money call, capping both tails of the position around the current spot.
Current CNTB snapshot
As of May 15, 2026, spot at $2.39, ATM IV 108.50%, IV rank 19.55%, expected move 31.11%. The collar on CNTB below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this collar structure on CNTB specifically: IV regime affects collar pricing on both sides; compressed CNTB IV at 108.50% typically pushes the short call premium to roughly offset the long put cost, with a market-implied 1-standard-deviation move of approximately 31.11% (roughly $0.74 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated CNTB expiries trade a higher absolute premium for lower per-day decay. Position sizing on CNTB should anchor to the underlying notional of $2.39 per share and to the trader's directional view on CNTB stock.
CNTB collar setup
The CNTB collar below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With CNTB near $2.39, the first option leg uses a $2.51 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed CNTB chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 CNTB shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 100 shares | Stock | $2.39 | long |
| Sell 1 | Call | $2.51 | N/A |
| Buy 1 | Put | $2.27 | N/A |
CNTB collar risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit roughly equals short-call strike minus cost basis plus net premium; max loss roughly equals cost basis minus long-put strike minus net premium. Breakeven shifts by the net premium.
CNTB collar payoff curve
Modeled P&L at expiration across a range of underlying prices for the collar on CNTB. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use collar on CNTB
Collars on CNTB hedge an existing long CNTB stock position; the long put sets a floor while the short call finances it, often run as a near-zero-cost hedge during expected volatility windows.
CNTB thesis for this collar
The market-implied 1-standard-deviation range for CNTB extends from approximately $1.65 on the downside to $3.13 on the upside. A CNTB collar hedges an existing long CNTB position with a protective put while financing the put cost via a short call; when the premiums roughly offset, the collar acts as a near-zero-cost insurance band around the current spot. Current CNTB IV rank near 19.55% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on CNTB at 108.50%. As a Healthcare name, CNTB options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to CNTB-specific events.
CNTB collar positions are structurally neutral (protective); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. CNTB positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move CNTB alongside the broader basket even when CNTB-specific fundamentals are unchanged. Always rebuild the position from current CNTB chain quotes before placing a trade.
Frequently asked questions
- What is a collar on CNTB?
- A collar on CNTB is the collar strategy applied to CNTB (stock). The strategy is structurally neutral (protective): A collar pairs long stock with a protective out-of-the-money put financed by a short out-of-the-money call, capping both tails of the position around the current spot. With CNTB stock trading near $2.39, the strikes shown on this page are snapped to the nearest listed CNTB chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are CNTB collar max profit and max loss calculated?
- Max profit roughly equals short-call strike minus cost basis plus net premium; max loss roughly equals cost basis minus long-put strike minus net premium. Breakeven shifts by the net premium. For the CNTB collar priced from the end-of-day chain at a 30-day expiry (ATM IV 108.50%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a CNTB collar?
- The breakeven for the CNTB collar priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current CNTB market-implied 1-standard-deviation expected move is approximately 31.11%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a collar on CNTB?
- Collars on CNTB hedge an existing long CNTB stock position; the long put sets a floor while the short call finances it, often run as a near-zero-cost hedge during expected volatility windows.
- How does current CNTB implied volatility affect this collar?
- CNTB ATM IV is at 108.50% with IV rank near 19.55%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.